TScan Therapeutics (TCRX) Current Assets (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Current Assets data on file, last reported at $132.8 million in Q1 2026.

• On a quarterly basis, Current Assets fell 47.9% year-over-year to $132.8 million in Q1 2026; TTM through Mar 2026 was $132.8 million, a 47.9% decrease from a year earlier, with the FY2025 full-year figure at $157.2 million, down 46.29% from the prior year.
• Current Assets for Q1 2026 stood at $132.8 million, down from $157.2 million in the prior quarter.
• Over the last five years, Current Assets for TCRX reached as high as $299.5 million in Q2 2024 and fell as low as $100.9 million in Q1 2023.
• Historically, Current Assets has averaged $193.0 million across 5 years, with a median of $188.2 million in 2025.
• Across the five-year window, Current Assets soared 87.24% in 2023 and sank 47.9% in 2026, its largest moves.
• Year by year, Current Assets stood at $124.1 million in 2022, then jumped by 56.48% to $194.2 million in 2023, then surged by 50.7% to $292.7 million in 2024, then plunged by 46.29% to $157.2 million in 2025, then slipped by 15.55% to $132.8 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $132.8 million in Q1 2026, $157.2 million in Q4 2025, and $188.2 million in Q3 2025.